TL;DR: The Centers for Medicare & Medicaid Services modified NCD 360 governing ventricular assist device coverage, effective January 9, 2026. Here's what billing teams need to know before submitting claims.
CMS ventricular assist device coverage policy under NCD 360 has been updated. This policy governs Medicare reimbursement for VADs used in post-cardiotomy support and long-term mechanical circulatory support for heart failure patients. The policy does not list specific CPT or HCPCS codes—but the clinical and facility criteria it sets are the real gatekeepers for your claims. Get those wrong, and you're looking at a claim denial before the device is even implanted.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | Ventricular Assist Devices — NCD 360 |
| Policy Code | NCD 360 |
| Change Type | Modified |
| Effective Date | January 9, 2026 |
| Impact Level | High |
| Specialties Affected | Cardiothoracic Surgery, Advanced Heart Failure Cardiology, Inpatient Hospital Billing, Cardiac Device Programs |
| Key Action | Confirm your facility holds CMS-approved credentialing and your multidisciplinary team meets the minimum qualifications before billing VAD implantation under this updated policy |
CMS Ventricular Assist Device Coverage Criteria and Medical Necessity Requirements 2026
NCD 360 is the National Coverage Determination governing Medicare coverage of ventricular assist devices. A VAD is surgically attached to one or both intact ventricles to help a weakened heart pump blood. If the native heart improves, the device can be removed—but many patients receive VADs as permanent, destination therapy.
CMS covers VADs under two nationally covered indications. Each has its own medical necessity criteria, and conflating them in your documentation is a fast path to denial.
Post-Cardiotomy Support
The first covered indication has been in place since October 18, 1993. VADs used for blood circulation support after open-heart surgery are covered—but only if the device has FDA approval for that use and is used exactly according to FDA-approved labeling instructions. No FDA approval for post-cardiotomy support? No coverage. No exceptions.
Left Ventricular Assist Devices for Heart Failure
The second covered indication is where most of the billing complexity lives. LVADs are covered for both short-term use (bridge-to-recovery, bridge-to-transplant) and long-term use (destination therapy). But a patient must meet all of the following to satisfy medical necessity:
| # | Covered Indication |
|---|---|
| 1 | NYHA Class IV heart failure |
| 2 | Left ventricular ejection fraction (LVEF) ≤ 25% |
| 3 | Inotrope dependence, OR a Cardiac Index (CI) < 2.2 L/min/m² while not on inotropes |
If the patient meets the CI threshold without inotrope dependence, they must also meet one of these two additional conditions:
| # | Covered Indication |
|---|---|
| 1 | On optimal medical management (OMM) per current heart failure practice guidelines for at least 45 of the last 60 days and failing to respond, OR |
| 2 | Advanced heart failure for at least 14 days and dependent on an intra-aortic balloon pump (IABP) or similar temporary mechanical circulatory support for at least seven days |
Every one of these criteria needs to be documented in the medical record before the claim goes out. This is not a policy where your clinical team can rely on the attending's summary note. Your prior authorization packet and claim documentation need to map directly to this checklist—NYHA class, LVEF measurement, inotrope status or CI value, duration on OMM or IABP.
Multidisciplinary Team Requirements
This is where the NCD 360 coverage policy gets unusually specific—and where facilities that aren't running a formal VAD program will run into trouble.
CMS requires that every patient receiving a VAD be managed by an explicitly identified, cohesive, multidisciplinary team. That team must include, at minimum:
| # | Covered Indication |
|---|---|
| 1 | At least one physician with cardiothoracic surgery privileges who has individually implanted at least 10 durable, intracorporeal LVADs in the previous 36 months, with activity in the last year |
| 2 | At least one cardiologist trained in advanced heart failure with clinical competence in VAD management—before and after placement |
| 3 | A VAD program coordinator |
| 4 | A social worker |
| 5 | A palliative care specialist |
The "10 LVADs in 36 months" threshold is not a facility-level number. It's individual. One surgeon who meets the threshold doesn't cover a second surgeon who doesn't.
All team members must be based at the facility. This matters if your program uses telemedicine consultants or rotating specialists from an affiliate site.
Facility Credentialing
Facilities must hold credentialing from a CMS-approved credentialing organization. CMS maintains a public list of approved organizations, approved standard versions, and credentialed facilities on its website. If your facility is not on that list, VAD billing under this coverage policy will not survive a medical necessity review.
Check the list now. Don't wait until a claim comes back denied.
CMS Ventricular Assist Device Exclusions and Non-Covered Indications
NCD 360 is explicit: all other VAD indications not listed under the nationally covered categories are non-covered. There is no gray area here. If the indication doesn't fit post-cardiotomy support or the LVAD heart failure criteria above, CMS will not reimburse it.
The one carve-out is clinical trials. VADs used in Category B investigational device exemption (IDE) clinical trials under 42 CFR 405, or as a routine cost in qualifying clinical trials under NCD section 310.1, may still be covered. If your facility participates in IDE trials involving VADs, loop in your compliance officer before billing. The coverage pathway and documentation requirements for trial-based claims are different from standard inpatient billing guidelines.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Post-cardiotomy VAD support (on or after October 18, 1993) | Covered | Not specified in policy | Device must have FDA approval for post-cardiotomy use; must follow FDA labeling exactly |
| LVAD for NYHA Class IV heart failure — inotrope dependent with LVEF ≤ 25% | Covered | Not specified in policy | CI threshold and OMM/IABP criteria apply if not inotrope dependent |
| LVAD for NYHA Class IV heart failure — CI < 2.2 L/min/m², on OMM ≥ 45 of last 60 days | Covered | Not specified in policy | Must be failing OMM per current guidelines |
| LVAD for NYHA Class IV heart failure — CI < 2.2 L/min/m², on IABP ≥ 7 days | Covered | Not specified in policy | Advanced HF duration of ≥ 14 days also required |
| LVAD — bridge-to-recovery | Covered | Not specified in policy | Must meet full medical necessity criteria above |
| LVAD — bridge-to-transplant | Covered | Not specified in policy | Must meet full medical necessity criteria above |
| LVAD — destination therapy | Covered | Not specified in policy | Must meet full medical necessity criteria above |
| All other VAD indications | Not Covered | Not specified in policy | No coverage outside nationally covered categories |
| VAD in Category B IDE clinical trials (42 CFR 405) | Covered (trial context) | Not specified in policy | Separate documentation and billing pathway; consult compliance |
| VAD as routine cost in qualifying clinical trials (NCD 310.1) | Covered (trial context) | Not specified in policy | Separate documentation and billing pathway; consult compliance |
CMS Ventricular Assist Device Billing Guidelines and Action Items 2026
The effective date for this modified policy is January 9, 2026. If your facility bills VAD implantations, these steps are not optional.
| # | Action Item |
|---|---|
| 1 | Verify your facility's credentialing status before January 9, 2026. Go to the CMS-approved facility list at cms.gov and confirm your facility appears under an approved credentialing organization and standard version. If you're not listed, no amount of correct documentation will save your claim. |
| 2 | Audit your surgeon's individual implant volume now. The policy requires at least one cardiothoracic surgeon with 10 or more durable, intracorporeal LVAD implants in the previous 36 months, plus activity in the last year. Pull the numbers. If your primary implanting surgeon is close to the threshold, document it carefully. If they fall short, your VAD billing is at risk. |
| 3 | Map every LVAD claim to the three-part medical necessity checklist. Your documentation must show NYHA Class IV status, LVEF ≤ 25%, and either inotrope dependence or CI < 2.2 L/min/m². For CI-based claims, also document OMM duration (minimum 45 of last 60 days) or IABP dependence (minimum 7 days, with 14+ days of advanced HF). Missing one element means a denied claim. |
| 4 | Confirm your multidisciplinary team is fully assembled and documented. All five required roles—cardiothoracic surgeon, advanced heart failure cardiologist, VAD coordinator, social worker, and palliative care specialist—must be on staff at the facility. Build a team roster into your VAD program documentation. CMS reviewers will look for it. |
| 5 | Update your prior authorization and pre-service documentation templates. If your prior authorization packet doesn't already include fields for NYHA class, LVEF value, CI measurement, inotrope status, OMM duration, and IABP duration, revise it before January 9, 2026. A complete prior auth submission is your first line of defense against denial. |
| 6 | Separate IDE trial claims from standard inpatient claims. If your facility runs VAD clinical trials, your billing team needs a clear process to flag trial patients and route their claims through the correct pathway. Billing a trial patient as a standard inpatient VAD claim—or vice versa—creates a reimbursement problem and a compliance problem. If you're not sure how your trial billing is set up, talk to your compliance officer now. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Ventricular Assist Devices Under NCD 360
The NCD 360 policy document does not list specific CPT, HCPCS, or ICD-10 codes. This is worth flagging directly: ventricular assist device billing uses procedure codes that are assigned and billed by your facility's coding team based on the specific device and procedure performed—but NCD 360 itself does not enumerate them.
This means your coders need to know the clinical criteria cold. The codes won't tell the story. The documentation has to.
Work with your cardiothoracic surgery coding team to confirm which CPT and ICD-10 codes your facility currently uses for VAD implantation, post-cardiotomy support, and destination therapy. Cross-reference those codes against CMS's Medicare Coverage Database to confirm no applicable Local Coverage Determination (LCD) from your Medicare Administrative Contractor (MAC) adds code-specific requirements on top of NCD 360. MAC-level LCDs can and do add layers to national policy—especially for high-cost cardiac device procedures.
If your MAC has issued an LCD or article related to VADs, that document will likely specify covered diagnosis codes. Pull it. Reconcile it with NCD 360. If there's a conflict or gap, that's a question for your compliance officer before the January 9, 2026 effective date.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.